SPYRE THERAPEUTICS, INC. (SYRE) Overview
- 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.74; Beat / miss (m).
- 1 Jul 2024: Period ending 30 Sept 2024; Estimate (m); Actual 1.06; Beat / miss (m).
- 1 Apr 2024: Period ending 30 Jun 2024; Estimate (m); Actual 0.59; Beat / miss (m).
- 1 Jan 2024: Period ending 31 Mar 2024; Estimate (m); Actual 0.72; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $103.82
- Previous close
- $84.72
- Change
- $19.10
- Change (%)
- 22.54%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- SYRE
- +158.59%
- S&P 500
- (m)
1 year
- SYRE
- +417.82%
- S&P 500
- (m)
3 years
- SYRE
- +591.55%
- S&P 500
- (m)
5 years
- SYRE
- -56.33%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
31 Mar 2026 ○ Estimate (m) ● Actual -0.74
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2026 | 31 Mar 2026 | (m) | -0.74 | (m) | (m) |
| 1 Jul 2024 | 30 Sept 2024 | (m) | 1.06 | (m) | (m) |
| 1 Apr 2024 | 30 Jun 2024 | (m) | 0.59 | (m) | (m) |
| 1 Jan 2024 | 31 Mar 2024 | (m) | 0.72 | (m) | (m) |
| 1 Jul 2023 | 30 Sept 2023 | (m) | 0.86 | (m) | (m) |
31 Dec 2023 ○ Estimate (m) ● Actual 13.76
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2023 | 31 Dec 2023 | (m) | 13.76 | (m) | (m) |
| 1 Jan 2022 | 31 Dec 2022 | (m) | -24.86 | (m) | (m) |
| 1 Jan 2021 | 31 Dec 2021 | (m) | -25.02 | (m) | (m) |
| 1 Jan 2020 | 31 Dec 2020 | (m) | -1.52 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
30 Sept 2024 ■ Revenue 0.00M ■ Earnings -69.03M — Profit margin (m)
31 Dec 2025 ■ Revenue 0.00M ■ Earnings -155.20M — Profit margin (m)
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $103.82 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning SYRE
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending 31 Dec 2025.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-155.20M
- Profit margin
- (m)
- Return on assets · 12 month
- -22.39%
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- 102.00
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 1.23M
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -7.88%*
- Total return · month
- -6.24%*
- Total return · quarter
- -6.04%*
- Total return · half year
- 79.06%*
- Total return · year to date
- 158.59%*
- Total return · 1 year
- 417.82%*
- Total return · 3 years
- 591.55%*
- Total return · 5 years
- -56.33%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- Revenue · 12 month
- $0.00
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Operating cash flow · 12 months
- $-169.25M
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
SPYRE THERAPEUTICS, INC. Overview
View more →(m)
(m)
- SEC CIK
- 1636282
- Industry (SIC)
- 2834 Pharmaceutical Preparations
- Country of operation
- United States
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, Massachusetts, 02453, United States
- Fiscal year end
- 1231
- Phone
- 6176515940
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |